Remission of Graves' Hyperthyroidism Predicted by Smooth Decreases of Thyroid-Stimulating Antibody and Thyrotropin-Binding Inhibitor Immunoglobulin During Antithyroid Drug Treatment
Authors:
- Nobuyuki TakasuNTNobuyuki Takasu
- Kei YamashiroKYKei Yamashiro
- Lchiro KomiyaLKLchiro Komiya
- Yukio OchiYOYukio Ochi
- Yasusi SatoYSYasusi Sato
- Atuo NagataANAtuo Nagata
- 1 October 2000
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 10 (10) , 891-896
Abstract
It is important to know whether a patient with Graves' disease will get into remission or not during antithyroid drug (ATD) treatment. Thyrotropin (TSH) receptor antibodies (TRAb) cause Graves' disease. Thyroid-stimulating antibody (TSAb) and TSH-binding inhibitor immunoglobulin (TBII) have been measured as TRAb to diagnose Graves' disease and to follow Graves' patients. Smooth decreases of TSAb and TBII during ATD treatment predict the remission of Graves' hyperthyroidism. We followed serial changes of TSAb and TBII in 58 Graves' patients before, during, and after ATD treatment; TSAb was measured as a stimulator assay, using porcine thyroid cells, and TBII as a receptor assay. Patterns of TSAb and TBII changes during ATD treatment differ from one patient to another. TSAb and TBII activities decreased and disappeared in 52 (group A) but continued to be high in the other 6 (group B); 39 of the 52 group A patients achieved remission, but all of the 6 group patients with persistently positive TSAb and TBII continued to have hyperthyroidism. No differences in the initial TSAb and TBII activities were noted between the 52 group A patients and the 6 group patients. Of the 52 group A patients in whom TSAb and TBII had disappeared, 44 had smooth decreases of TSAb and TBII (group A1), and 8 had complex changes of TSAb and/or TBII (group A2); 36 of the 44 group A1 patients (82%) but only 3 of the 8 group A2 patients (37%) continued to be in remission more than 1 year after ATD discontinuation. The number of remission in group A1 was significantly larger than that in group A2. No differences in the initial TSAb and TBII activities were noted between group A1 and group A2. More than 80% of group A1 patients, who had smooth decreases of TSAb and TBII, continued to be in remission longer than 1 year. We demonstrated that smooth decreases of TSAb and TBII during ATD treatment predicted the remission of Graves' hyperthyroidism. The Graves' patients can be classified into A1, A2, and groups according to the patterns of TSAb and TBII changes during ATD treatment. Group A1 patients, who had smooth decreases of TSAb and TBII, had higher rate of remission than the others. Smooth decreases of TSAb and TBII during the early phase of ATD treatment are a reliable predictor of the remission.Keywords
This publication has 9 references indexed in Scilit:
- Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves’ patients and in 686 normal subjectsJournal of Endocrinological Investigation, 1997
- Simple and reliable method for predicting the remission of Graves’ disease: Revised triiodothyronine-suppression test, indexed by serum thyroxineJournal of Endocrinological Investigation, 1995
- Advances in statistical methodology for the evaluation of diagnostic and laboratory testsStatistics in Medicine, 1994
- Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' diseaseEuropean Journal of Endocrinology, 1989
- AN ANALYSIS OF THYROTROPHIN RECEPTOR BINDING AND THYROID STIMULATING ACTIVITIES IN A SERIES OF Graves' SERAClinical Endocrinology, 1985
- Clinical Experience with a Human Thyroid Cell Bioassary for Thyroid-Stimulating Immunoglobin *The Journal of Clinical Endocrinology & Metabolism, 1984
- Functionality of Thyroid-Stimulating Antibodies Assessed by Cryopreserved Human Thyroid Cell Bioassay*The Journal of Clinical Endocrinology & Metabolism, 1983
- A New in Vitro Assay for Human Thyroid Stimulator Using Cultured Thyroid Cells: Effect of Sodium Chloride on Adenosine 3′,5′-Monophosphate Increase*The Journal of Clinical Endocrinology & Metabolism, 1982
- Detection and Properties of TSH-Binding Inhibitor Immunoglobulins in Patients with Graves’ Disease and Hashimoto’s Thyroiditis*The Journal of Clinical Endocrinology & Metabolism, 1978